12/12/2024
Dr. Lynnette Averill and Baylor College of Medicine are thrilled to be initiating enrollment for a Texas state-funded trial of psilocybin-assisted therapy for Veterans with PTSD.
This study is supported by HB1802, which passed with nearly unanimous support in the Texas House and Senate and was landmark legislation. The study will trial two doses of psilocybin delivered with supportive therapy before, during, and after dosing. Psilocybin is currently a DEA-classed Schedule 1 drug and experimental treatment with Breakthrough Therapy status through the FDA. Consequently, there are carefully considered eligibility criteria for participation to help ensure safety.
If you are interested in learning more, please scan the QR code with your phone to complete a brief pre-screening questionnaire. You can also contact our study team at [email protected] to have the link sent to you.
